Historical Valuation
GIANT BIOGENE (02367) is now in the Fair zone, suggesting that its current forward PE ratio of 13.42 is considered Fairly compared with the five-year average of 21.37. The fair price of GIANT BIOGENE (02367) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：36.64
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
GIANT BIOGENE (02367) has a current Price-to-Book (P/B) ratio of 3.54. Compared to its 3-year average P/B ratio of 7.87 , the current P/B ratio is approximately -54.98% higher. Relative to its 5-year average P/B ratio of 8.72, the current P/B ratio is about -59.39% higher. GIANT BIOGENE (02367) has a Forward Free Cash Flow (FCF) yield of approximately 4.50%. Compared to its 3-year average FCF yield of 3.35%, the current FCF yield is approximately 34.24% lower. Relative to its 5-year average FCF yield of 3.29% , the current FCF yield is about 36.69% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 02367 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02367 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02367 currently overvalued or undervalued?
GIANT BIOGENE (02367) is now in the Fair zone, suggesting that its current forward PE ratio of 13.42 is considered Fairly compared with the five-year average of 21.37. The fair price of GIANT BIOGENE (02367) is between to according to relative valuation methord.
What is GIANT BIOGENE (02367) fair value?
02367's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GIANT BIOGENE (02367) is between to according to relative valuation methord.
How does 02367's valuation metrics compare to the industry average?
The average P/S ratio for 02367's competitors is , providing a benchmark for relative valuation. GIANT BIOGENE Corp (02367) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for GIANT BIOGENE (02367) as of Jan 16 2026?
As of Jan 16 2026, GIANT BIOGENE (02367) has a P/B ratio of 3.54. This indicates that the market values 02367 at 3.54 times its book value.
What is the current FCF Yield for GIANT BIOGENE (02367) as of Jan 16 2026?
As of Jan 16 2026, GIANT BIOGENE (02367) has a FCF Yield of 4.50%. This means that for every dollar of GIANT BIOGENE’s market capitalization, the company generates 4.50 cents in free cash flow.
What is the current Forward P/E ratio for GIANT BIOGENE (02367) as of Jan 16 2026?
As of Jan 16 2026, GIANT BIOGENE (02367) has a Forward P/E ratio of 13.42. This means the market is willing to pay $13.42 for every dollar of GIANT BIOGENE’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for GIANT BIOGENE (02367) as of Jan 16 2026?
As of Jan 16 2026, GIANT BIOGENE (02367) has a Forward P/S ratio of 4.79. This means the market is valuing 02367 at $4.79 for every dollar of expected revenue over the next 12 months.